open access

Vol 55, No 1 (2021)
Letter to the Editors
Published online: 2021-01-29
Submitted: 2020-11-25
Accepted: 2021-01-08
Get Citation

Lacosamide and myoclonic seizures: what is the risk of aggravation?

Magdalena Bosak, Kamil Wężyk, Agnieszka Słowik
DOI: 10.5603/PJNNS.a2021.0008
·
Pubmed: 33512706
·
Neurol Neurochir Pol 2021;55(1):107-109.

open access

Vol 55, No 1 (2021)
Letters to the Editors
Published online: 2021-01-29
Submitted: 2020-11-25
Accepted: 2021-01-08

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

lacosamide, myoclonic seizures, aggravation, exacerbation

Supp./Additional Files (5)
Figure 1 Suppl. Mat.
Download
932KB
Figure 2 Suppl. Mat.
Download
818KB
Figure 3 Suppl. Mat.
Download
792KB
Figure 4 Suppl. Mat.
Download
879KB
Figure 5 Suppl. Mat.
Download
673KB
About this article
Title

Lacosamide and myoclonic seizures: what is the risk of aggravation?

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 55, No 1 (2021)

Article type

Letter to the Editors

Pages

107-109

Published online

2021-01-29

DOI

10.5603/PJNNS.a2021.0008

Pubmed

33512706

Bibliographic record

Neurol Neurochir Pol 2021;55(1):107-109.

Keywords

lacosamide
myoclonic seizures
aggravation
exacerbation

Authors

Magdalena Bosak
Kamil Wężyk
Agnieszka Słowik

References (8)
  1. Vossler DG, Knake S, O'Brien TJ, et al. SP0982 trial investigators. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2020; 91(10): 1067–1075.
  2. Chaves J, Sander JW. Seizure aggravation in idiopathic generalized epilepsies. Epilepsia. 2005; 46 Suppl 9: 133–139.
  3. Wężyk K, Słowik A, Bosak M. Predictors of remission in patients with epilepsy. Neurol Neurochir Pol. 2020; 54(5): 434–439.
  4. Swaminathan A, Kapoor S. A case report of exacerbation of myoclonus in idiopathic generalized epilepsy from use of lacosamide. Neurology. 2015; 84 (14 Suppl.) Abstracts: AAN 67th Annual Meeting.
  5. Birnbaum D, Koubeissi M. Unmasking of myoclonus by lacosamide in generalized epilepsy. Epilepsy Behav Case Rep. 2017; 7: 28–30.
  6. Belcastro V, Arnaboldi M, Taborelli A, et al. Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine. Epilepsy Behav. 2011; 20(3): 589–590.
  7. Abarrategui B, García-García ME, Toledano R, et al. Lacosamide for refractory generalized tonic-clonic seizures of non-focal origin in clinical practice: A clinical and VEEG study. Epilepsy Behav Case Rep. 2017; 8: 63–65.
  8. Wechsler RT, Yates SL, Messenheimer J, et al. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension. Epilepsy Res. 2017; 130: 13–20.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl